Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) today announced that it will increase the sample size for Part A of its Phase 2 ASCEND clinical trial, which is enrolling a mGluR mutation positive genetic subset of pediatric and adolescent patients with Attention Deficit Hyperactivity Disorder (ADHD), to confirm response to AEVI-001 in these patients.
June 12, 2018
· 4 min read